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Purpose: Many past human immunodeficiency virus (HIV) clinical trials have struggled to recruit 
and retain female participants due to their encounters with potential barriers that prevented 
the participants’ initial or continued involvement in the clinical trials. Patient recruitment and 
retention rates are crucial to the success of clinical research trials. The objective of this study 
was to identify common barriers to recruitment and retention of female participants and to 
identify the common best practices used to address these barriers. 
Methods A literature search was conducted to identify articles relating to the recruitment and 
retention of female participants in HIV/AIDS clinical trials. Keywords and search terms were 
used in PubMed, BASE (Bielefeld Academic Search Engine), and Web of Science. A total of 48 
articles were found and narrowed down using 17 out of the 27 checklist items provided by the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) to help 
determine each article’s eligibility for inclusion in this study. 
Results: In the twenty-five articles selected for this study, eight common recruitment and 
retention barriers were identified. Researchers addressed these barriers by utilizing several 
common best practices to improve recruitment and retention rates. 
Conclusion: By implementing the best practices found in this study, healthcare providers and 
researchers will be able to overcome the challenges in recruiting and retaining female 
participants in future HIV/AIDS clinical trials. 
Primary Reader and Advisor: Dr. Jeffrey Kantor  
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According to the National Institute of Health, clinical studies involve research using 
voluntary human subjects or participants. The purpose of these studies is to help contribute 
medical knowledge to the healthcare and research communities. There are two main types of 
clinical studies: observational studies and clinical trials (interventional studies).1 
 In clinical trials, the participants receive specific interventions according to the research 
plan created by the principal investigator, often a medical doctor. Interventions may include, 
but are not limited to, pharmaceutical products, drugs, devices, procedures, and diet.  
 Clinical studies are conducted to advance medical knowledge related to treatment, 
diagnosis, prevention of disease. Clinical studies can also help doctors determine other aspects 
of care, such as improving the quality of life for people with chronic illnesses such as HIV.2 The 
goal of clinical trials is to determine if a new test or treatment is safe and if it works. 
 
1.1 Importance of Participating in Clinical Trials 
 
                                                 
1 Learn About Clinical Studies. (n.d.). Retrieved from https://clinicaltrials.gov/ct2/about-studies/learn#WhatIs 








A clinical study is conducted based on a research plan or protocol. Protocols are intended to 
answer specific research questions and to protect participants. Protocol information may 
include, but is not limited to:  
• Reasons for conducting a study,  
• Eligibility criteria (a predetermined group of people based on gender, race, age, 
disease, etc.)  
• Number of participants needed 
• Schedule of procedures and tests  
• Type of drugs administered 
• Length of study 
  
Factors that could lead to poor results in clinical trials may include the following: length 
of the clinical study, costs, and time burdens on patients. Issues can arise during clinical trials 
that may result in clinical failures, including safety issues, lack of efficacy, lack of funding, and 
lack of patient recruitment or retention.3  
An article by Hwang et al. 4 assessed 640 phase 3 trials; the authors found that 54% 
failed in clinical development and 57% failed due to inadequate efficacy. Many reasons could 
contribute to failed efficacy, such as non-response to treatment drugs, flawed study design, 
small sample size due to patient dropouts, and insufficient enrollment, causing an 
                                                 
3 Fogel D. B. (2018). Factors associated with clinical trials that fail and opportunities for improving the likelihood of 
success: A review. Contemporary clinical trials communications, 11, 156–164. 
https://doi.org/10.1016/j.conctc.2018.08.001 
4 Hwang T.J., Carpenter D., Lauffenburger J.C., Wang B., Franklin J.M., Kesselheim A.S. Failure of investigational 






inappropriate statistical endpoint. Regardless of the type of research, clinical trials are heavily 
dependent on the participation of patients to conduct a research study successfully.  
The purpose of a clinical trial is to answer a research question; for this to happen, 
researchers must recruit an adequate number of participants to conduct the clinical study and 
must retain as many of those participants as possible. In clinical trials where either recruitment 
or retention falls short, the study may fail to achieve its purpose. Researchers will be unable to 
answer the research question, and the enrolled participants would have joined the clinical 
research study for no purpose. Recruitment and retention of participants are essential in the 
success of clinical studies, but maintaining high recruitment and retention rates in clinical trials 
is a significant challenge across the research community. 
Chapter 2  
Review of the Literature   
2.1 History of HIV Clinical Trials  
According to the National Institute of Allergy and Infectious Disease (NIAID), in 1984, 
Human Immunodeficiency Virus (HIV) was identified as the cause of Acquired 
Immunodeficiency Syndrome (AIDS). Historically, vaccination has been the preferred method 
for protecting people from infectious diseases. In 1987, the first HIV vaccine clinical trial opened 
at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland. The Phase 1 
trial enrolled 138 healthy, HIV-negative volunteers. The vaccine showed no serious adverse 
effects. Although some other methods and techniques do help prevent HIV infection, 





two approaches to HIV vaccine development: 1. A Theoretical Approach; 2. An Empirical 
Approach.5 This thesis will mainly focus on an empirical approach.  
A Theoretical Approach is based on theory and involves establishing an understanding of 
the immune response to HIV infection and finding ways to generate and enhance that response 
through vaccination. Some strategies aim to prevent HIV infection through an antibody-
mediated response, while others strive to create a protective cellular response.6 
 An Empirical Approach to HIV vaccine development relies on observation and 
experimentation to move vaccine candidates into clinical trials. The sole purpose of a vaccine 
trial is to contribute towards scientific and medical progress. Many investigational vaccines that 
initially worked in laboratory and animal studies did not do well in human clinical trials. An 
example of this was in 2007, where two large HIV vaccine clinical trials, known as the STEP and 
Phambili, were run. The administration of vaccinations ended without success. After reviewing 
the data put out by an independent data safety and monitoring board, it was concluded that 
the data did not demonstrate that the vaccine could either prevent HIV infection or affect the 
course of the disease in people who acquired HIV; however, in 2003, the Thai HIV RV144 study 
in Thailand was the first large clinical trial to demonstrate the effectiveness of an investigational 
HIV vaccine. "At the end of the 3.5-year study period, investigators observed a 31 percent 
reduction in HIV infection among vaccine recipients compared to those who received a placebo. 
                                                 
5 History of HIV Vaccine Research. (n.d.). Retrieved from https://www.niaid.nih.gov/diseases-conditions/hiv-
vaccine-research-history 






The trial, which involved more than 16,000 adult participants, was sponsored by the US Military 
HIV Research Program, in collaboration with NIAID and other partners”.7  
The RV144 study evaluated the safety and effectiveness of a prime-boost combination 
of two vaccine components given in sequence: ALVAC-HIV and AIDSVAX B/E. The vaccine 
regimen appeared to provide the most significant protective effect during the first year after 
vaccination, providing a 60 percent reduction in infection risk, but over time the effectiveness 
decreased. The results from the study indicated the vaccines were safe, well-tolerated, and 
suitable for a larger scale research clinical research.8 The NIAID and its partners continue to 
invest in multiple approaches to develop an effective HIV vaccine.  
2.2 History of Clinical Trials Involving Women   
 In the past several decades, there has been a significant shift in scientific, ethical, and 
legal standpoints regarding the inclusion of women in clinical trials conducted in the United 
States. There is a clinical requirement for testing drugs in specific populations, such as women, 
to ensure correct dose regimens and to minimize the adverse effects of the treatment. The 
women's movement between the 1960s and 1970s began to take effect in the 1980s when the 
US Public Health Service established a task force on women's health. The task force concluded 
that a lack of research in women's health had compromised the quality of available information 
                                                 
7 An Empirical Approach to HIV Vaccine Development. (n.d.). Retrieved from https://www.niaid.nih.gov/diseases-
conditions/empirical-approach 







on diseases affecting women and the health care women receive. The task force recommended 
that steps be taken to ensure that more women's participation was included in clinical trials.9  
The 1977 Food and Drug Administration (FDA) guidelines had excluded women of 
childbearing potential from the first and the earliest part of the second phase of clinical trials. 
Sponsors often interpreted the restriction more generally and limited entry of women into the 
later stages of drug trials. The FDA recognized that failure to include diverse populations in 
trials for new drugs could lead to treatment protocols focused more on middle-aged, white 
males. In a 1983 survey of 11 pending new drug applications, the agency found substantial 
enrollment disparities, with women and the elderly significantly underrepresented in some 
disease study categories.10 In response, the NIH issued a policy in 1986 to encourage the 
inclusion of women in federally funded research studies; however, the US General Accounting 
Office (GAO) found that the NIH had made little progress concerning implementing its policy. 
This failure led to the enactment of The Women's Health Equity Act of 1990. After the passing 
of the Act, NIH created an Office for Research on Women's Health to ensure that women's 
health research is an integral part of the scientific fabric at NIH and throughout the scientific 
community.11 
Many factors can influence drug responses in people such as age, gender, race, and pre-
existing diseases. Any of these can influence healthcare providers’ choices of medications for 
their patients. For women, hormonal variations associated with the menstrual cycle, 
                                                 
9 Inclusion of Women in Clinical Trials: A Historical Overview of Scientific Ethical and Legal Issues Merkatz, Ruth B. 
Journal of Obstetric, Gynecologic & Neonatal Nursing, Volume 27, Issue 1, 78 – 84 
10 Inclusion of Women in Clinical Trials: A Historical Overview of Scientific Ethical and Legal Issues Merkatz, Ruth B. 
Journal of Obstetric, Gynecologic & Neonatal Nursing, Volume 27, Issue 1, 78 - 84 
11 Inclusion of Women in Clinical Trials: A Historical Overview of Scientific Ethical and Legal Issues Merkatz, Ruth B. 





menopause, oral contraceptive use, or estrogen supplementation may cause the drug to have a 
different effect on participants; therefore, the value of individualized treatment for a specific 
population became essential and drove the need to include women in clinical trials for AIDS 
therapy.  
According to the AIDS Service Center of the HIV Law Project, in January 1992, only 1,151 
women had been included among the 14,799 participants enrolled in the AIDS Clinical Trials 
Group studies sponsored by the NIAID.12 To ensure that new drugs would be evaluated 
adequately in women, in 1993, the FDA issued its Guideline for the Study and Evaluation of 
Gender Differences in the Clinical Evaluation of Drugs. According to the guidelines, researchers 
were to include a "reasonable" number of women in new clinical trials. The instructions also 
highlighted the need to assess possible pharmacokinetic differences (drug concentrations in the 
blood and tissues based on gender) and conduct pharmacodynamics (effect of drugs on the 
body) studies to evaluate the body's response to a given level of a drug when efficacy, rates of 
adverse events, and dose-response differed by gender.  
Examination of drugs relative to women's natural hormonal background was required, 
as were drug interaction studies with hormonal contraceptive agents, and hormone 
replacement therapy. At the same time, the guideline influenced the agency's decision to 
reverse the 1977 policy that had effectively barred most women of childbearing potential from 
participating in the early stages of clinical trials.13 The new requirements for the inclusion of 
                                                 
12 Pearl et al., 1992Pearl, M., Banzhaf, M., Leger, A., and Long, I.L. Women in U.S. government clinical 
trials. Amsterdam, Netherlands; 1992 (VIII International Conference on AIDS, 8(2:B235)) 
13 Inclusion of Women in Clinical Trials: A Historical Overview of Scientific Ethical and Legal Issues Merkatz, Ruth B. 






women in federally funded clinical trials also were integrated into the NIH Revitalization Act of 
1993. One year later, a new NIH guideline was jointly issued by the Office of Research on 
Women's Health to ensure that women and their subpopulations were included in all human 
subject research. Importantly, these groups must be able to participate in Phase 3 clinical trials 
to allow an accurate analysis of differences in intervention effects. Grant proposals being 
considered by any institute within the NIH had to be reviewed for compliance with this 
guideline, and funding may have been denied if guidelines were not met.14 Although progress 
has been made, women still appear to be underrepresented in some important clinical trials, 
particularly in the area of HIV and AIDS.15,16 
According to the 2006 CDC HIV/AIDS Surveillance Report of the estimated 491,727, 
HIV/AIDS cases in US 27% (132,766) were female. Figure 1 illustrates the number of women 
living with HIV/AIDS per year between the years of 2001 to 2006. Female HIV/AIDS has 
increased steadily from 101,398 cases in 2001 to 131,195 cases in 2006, a 23% increase. With 
an average of 117,444 HIV/AIDS cases throughout six years. 
                                                 
14 Inclusion of Women in Clinical Trials: A Historical Overview of Scientific Ethical and Legal Issues Merkatz, Ruth B. 
Journal of Obstetric, Gynecologic & Neonatal Nursing, Volume 27, Issue 1, 78 – 84 
15 Institute of Medicine (US) Committee on Ethical and Legal Issues Relating to the Inclusion of Women in Clinical 
Studies; Mastroianni AC, Faden R, Federman D, editors. Women and Health Research: Ethical and Legal Issues of 
Including Women in Clinical Studies: Volume I. Washington (DC): National Academies Press (US); 1994. 2, Women's 
Participation in Clinical Studies. Available from: https://www.ncbi.nlm.nih.gov/books/NBK236535/ 
16 Metch, B., Frank, I., Novak, R., Swann, E., Metzger, D., Morgan, C., . . . Koblin, B. (2013). Recruitment of urban  









2.2 Figure 1: Female living with HIV/AIDS in the US from 2001-2006 data retrieved from  
https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-report-2005-vol-17.pdf 
 
As female HIV/AIDS cases increase steadily in the US, there is a need to reduce the number of 
challenges/barriers that affect the amount of women participation in HIV/AIDS clinical research. 
There is a limited amount of information available for HIV/AIDS clinical trials that involve 
women.  
In 2014 twenty three percent of all United States HIV cases were women. Most data 
available to the public regarding the effectiveness and safety of HIV drugs were based on 
research studies done on men.17 With a limited number of clinical research studies done on 
women living with HIV/AIDS, there is not an adequate amount of information regarding the 
effectiveness and safety of HIV drugs that were administered to women. Although there was an 
increase in clinical studies done on HIV prevention and treatment, women’s participation 
remained low.  
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2.3 Issues of Recruitment and Retention 
In recruitment and retention of a diverse population in antiretroviral (ARV) clinical 
research. Approximately twenty-five percent of new HIV diagnoses in the United States were 
women.  Although there has been an increase in clinical trials, women remain 
underrepresented in clinical trials of ARV agents for HIV.18 Although there has been an increase 
in clinical trials, women remain underrepresented in clinical trials of ARV agents for HIV.19 As a 
result, current treatment guidelines are based on data from clinical trials that primarily enrolled 
men. Although the number of women recruited into clinical trials has been increasing, 
recruitment and retention of ‘treatment-experienced’ (An HIV patient that has previously or is 
currently taking antiretroviral drugs) women in trials have been less successful.20 
Several barriers prevented the successful recruitment and retention of women in clinical 
trials. In 2005, the Cargill and Stone article found that women who occupy primary care roles in 
their families placed family commitments above their own medical needs. Additional factors 
that impacted regular access to healthcare and led to missed medical appointments included 
domestic violence/threats of violence, the use of illicit drugs, and perceived stigma about their 
HIV status.21 Innovative approaches to trial design and conduct are required to overcome the 
                                                 
18 Centers for Disease Control and Prevention. HIV/AIDS among women. 
www.cdc.gov/hiv/topics/women/resources 
/factsheets/pdf. [Jul 20;2010] www.cdc.gov/topics/women/resources/factsheets/pdf. 
19 Falcon, R., Bridge, D. A., Currier, J., Squires, K., Hagins, D., Schaible, D., . . . Mrus, J. (2011). Recruitment and  
retention of diverse populations in antiretroviral clinical trials: practical applications from the gender, race and  
clinical experience study. J Womens Health (Larchmt), 20(7), 1043-1050. doi:10.1089/jwh.2010.2504 
20 Falcon, R., Bridge, D. A., Currier, J., Squires, K., Hagins, D., Schaible, D., . . . Mrus, J. (2011). Recruitment and   
retention of diverse populations in antiretroviral clinical trials: practical applications from the gender, race and  
clinical experience study. J Womens Health (Larchmt), 20(7), 1043-1050. doi:10.1089/jwh.2010.2504 






barriers and achieve successful participation in clinical trials. The scientific evidence and clinical 
experience suggest that there may be multiple factors limiting the recruitment and retention of 
female subjects. For example, a young woman with a family may be hesitant to enroll in a study 
that presents potential risks to her safety, livelihood, and children. A working mother may also 
be reluctant to participate because she may be unable to incorporate the behavioral 
requirements of the study into her daily schedule.22  
2.4 Barriers of Recruitment and Retention in Women 
Many factors contributed to the absence of women participants in clinical trials, such as 
safety of the trials, voluntary withdrawals, distrust of the medical establishment, stigma, lack of 
community support, lack of childcare, lack of information about the study, and lack of 
transportation. These factors often played a vital role and affected the willingness of women to 
participate in research trials.23 In a study conducted by Loufty et al. (2014), a survey was sent 
out to 38 site coordinators around Ontario, Canada, who were able to recruit 490 HIV positive 
women. The survey consisted of questions regarding study recruitment barriers. 34 out of 38 
surveys were returned. Of those returned, 31 respondents were women. Figure 2 shows 
recruitment barriers of women in HIV clinical trials: 59% for the sensitivity of research topic and 
                                                 
22 Institute of Medicine (US) Committee on the Ethical and Legal Issues Relating to the Inclusion of Women in 
Clinical Studies. (1999, January 1). Recruitment and Retention of Women in Clinical Studies: Theoretical 
Perspectives and Methodological Considerations. Retrieved from 
https://www.ncbi.nlm.nih.gov/books/NBK236563/. 







time constraints, at 53% for language barriers, 47% HIV disclosure/ Stigma issues, and 41% for 
childcare, transportation, fear of research, and lack of trust.24  
 
2.4 Figure 2: Recruitment Barriers of Women in HIV Clinical Trials 
 
 Clinical research investigators have been found to not perform or report any gender 
analysis results, and have been found to recruit inadequate numbers of women to support the 
kind of subgroup analysis that would be needed to resolve these gender-specific questions.25 
Although current policies requiring the inclusion of women in clinical studies are in place, 
recruitment and retention of women in HIV clinical trials remain low. There is still inadequate 
                                                 
24 Loutfy, M. R., V, L. K., Mohammed, S., Wu, W., Muchenje, M., Masinde, K., … Tharao, W. (2014, December 19). 
Recruitment of HIV-Positive Women in Research: Discussing Barriers, Facilitators, and Research Personnel's 
Knowledge. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302460/. 
25 Mastroianni, A. C., Faden, R. R., & Federman, D. D. (1994). Women and health research ethical and legal issues of 





research data available for clinical trials with women participation, and many unanswered 
questions about gender-based differences in response to treatments remain.     
2.5 Study Purpose 
Based on the review of literature, women recruitment and retention rates in clinical 
trials remain low. An increase in recruitment and retention of female participants is needed to 
increase the validity of the clinical trial findings. Without the recruitment and retention of 
women in clinical trials, gender differences in response to medical treatment will remain 
unknown. This study will identify the common barriers of recruitment and retention of women 
in HIV/AIDS clinical trials and will identify the best practices to recruit and retain female 
participants in clinical trials.  
2.6 Why is This Study Important?  
Increasing the recruitment and retention of women in clinical trials is important to 









Many past human immunodeficiency virus (HIV) clinical trials have struggled to recruit 
and retain female participants due to their encounters with potential barriers that prevented 
the participants’ initial or continued participation in the clinical trials. Multiple studies found 





still affects many women in the US, and there is a need to recruit and retain participants in 
HIV/AIDS clinical trials.26 Studies have found that patients that withdrew early from clinical 
trials were unable to complete their treatment, resulting in disease progression.27,28 A high rate 
of participation in clinical trials is crucial to the success of treatment programs in the total 
population of infected persons of both sexes. This study will focus on reviewing available data 
and identifying the best practices to overcome the common barriers of women recruitment and 
retention in HIV/AIDS clinical trials. 
 
Chapter 4  
Methodology  
In order to find relevant data related to women’s participation in HIV/AIDS clinical trials, 
keywords and terms were used in PubMed, BASE (Bielefeld Academic Search Engine), and Web 
of Science search portals. Although there are many additional search engines/portals available, 
these options were used for this study due to their extensive database of clinical and 
biomedical literature. Examples of search terms included a) HIV/AIDS clinical trial with women; 
b) recruitment and retention of women in HIV/AIDS clinical trials; c) Women HIV recruitment 
AND retention barriers; and d) Successful strategies for recruitment of women participants in 
                                                 
26 Falcon, R., Bridge, D. A., Currier, J., Squires, K., Hagins, D., Schaible, D., … GRACE Study Group. (2011, July). 
Recruitment and retention of diverse populations in antiretroviral clinical trials: practical applications from the 
gender, race and clinical experience study. Retrieved from 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3130514/. 
27 Grewe, M. E., Ma, Y., Gilbertson, A., Rennie, S., & Tucker, J. D. (2016). Women in HIV cure research: multilevel 
interventions to improve sex equity in recruitment. Retrieved from 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4780361/. 
28 Krubiner, C. B., Faden, R. R., Cadigan, R. J., Gilbert, S. Z., Henry, L. M., Little, M. O., … Lyerly, A. D. (2016, 






clinical trials. This study included articles related to the participation of women, the recruitment 
and retention of women subjects, the retention strategies and factors related to withdrawals of 
female participants, and the successful implementation of common best practices to improve 
women’s participation in HIV/AIDS clinical studies. 
The articles were further examined using the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) checklist. PRISMA is used for the reporting of reviews and 
evaluations of randomized clinical trials and helps authors report a wide range of systematic 
reviews and meta-analyses that assess studies relating to healthcare intervention.29 The 
PRISMA 2009 checklist includes 27 checklist items that focus on study details such as objectives, 
selection criteria, data collection processes, summaries of evidence, risks of bias across studies, 
limitations, and overall conclusions. These checklist items were used to help identify articles 
that described common barriers to recruitment and retention of women in HIV/AIDS clinical 
trials, and to identify the common best practices to minimize under-enrollment and participant 
withdrawals from clinical studies. Table 1, shown below, includes all the PRISMA criteria factors 
that were used for the selection process. Eighteen of these checklist items were used as the 
selection criteria for this study. 
Topics/Section Checklist items Used for 
Selection 
Criteria 
Not used for 
Selection 
Criteria 
Title Identify the report as a 
systematic review, meta-




Provide a structured summary X  
                                                 






Introduction Describe the logic for the review 
in the context of what is already 
known 
               X  
Objectives Provide an explicit statement of 
questions being addressed with 
reference to participants 
               X  





Specify study characteristics 





Describe all information sources   X  
Search Present full electronic search 
strategy for at least one 
database 
    X  
Study Selection State the process for selecting 
studies 
  X  
Date Collection Describe the method of data 
extraction from reports 
                X  
Data items List and define all variables (e.g. 
PICO, funding source ) 
 X 
Risk and bias Describe methods used for 
assessing risk of bias during 




State the principal summary 




Describe the methods of 
handling data and combining 
results of studies 
X  
Risk of bias 
across studies 
Specify any assessment of risk of 









Describe methods of additional 
analyses (subgroup analyses, 
meta-regression) 
 X 
Results Give numbers of studies 
screened, assessed for eligibility, 
and included in the review, with 





For each study, present 
characteristics for which data 
were extracted with citations 
X  
Risk of bias 
within studies 






For all outcomes considered X  
Synthesis of 
results 
Present results of each meta-
analysis done, including 
confidence intervals and 
measures of consistency 
 X 
Risk of bias 
across studies 
Present results of any 




Give results of additional 
analyses, if done 
 X 
Discussion Summarize the main findings 
including the strength of 
evidence for each main 
outcome 
X  
Limitation Discuss limitations at study and 
outcome level 
X  
Conclusion Provide a general interpretation 
of the results in the context of 
other evidence, and implications 
for future research 
                 X  
Funding Describe source of funding  X 
Total 27 checklist items 18 items 
included 
9 items not 
included 
4.1 Table 1: PRISMA 2009 Checklist  
Source: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for 







A total of 101 records were identified using key terms in PubMed, BASE, and Web of 
Science search portals and were put into an Excel spreadsheet. Articles were then sorted by 
author, title, and year. Fifty-three results were found to be duplicates and were removed. The 
48 remaining records were then screened using the articles’ abstracts. After this review, 17 
articles contained clinical data that were unrelated to the disease of interest and were 
excluded. The remaining 31 full-text articles were assessed for eligibility. These were further 
analyzed by looking at the articles’ data results, and six were excluded due to the inclusion of 
transgender men/women, children, and infants. Twenty-five full-text articles remained and 
were thoroughly examined.  
Using the PRISMA checklist for selection criteria, articles were then sorted into two 
categories: qualitative and quantitative articles. Of these studies, 16 were categorized into 
qualitative synthesis, which involved one-on-one interactions between staff and participants, 
and healthcare providers’ observations. The remaining nine studies were categorized into 
quantitative synthesis, which included surveys and questionnaires provided by the researchers.  
Comparative analysis of the 25 articles identified common practices used for recruiting 
female participants in HIV/AIDS clinical trials. Each article was reviewed using the same 
method: by examining the common barriers and common best practices in recruiting and 
retaining women participants. Figure 3, shown below, was used to give a graphical 






4.2 Figure 3: PRISMA 2009 Flow Diagram Flow diagram for the systematic review of qualitative 
and quantitative studies regarding recruitment barriers and successful strategies of women in 




The 25 studies showed eight common recruitment and retention barriers. These barriers 
were identified through observation by the study subjects’ healthcare providers or a follow-up 
survey that was given by the research staff. 
                                                 
30Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic 






There were 16 (64%) qualitative articles and 9 (36%) quantitative articles. Of the 
qualitative articles; 75% (n=12) of the articles recorded data during a one-on-one interaction 
between healthcare staff and participants, 62.5% (n=10) of the articles used observations from 
healthcare providers to record data relating to recruitment and retention rates of women in 
clinical trials, and 25% (n=4) of the articles mentioned the impact of community social groups 
on enrollment in clinical trials. Of the quantitative articles, 33.3% (n=3) of the articles recorded 
data using surveys provided to participants by clinical staff, and 66.6% (n=6) of the articles used 

















Impact of Social 
groups 
No. (%) 
Qualitative 16 (64.0) 12 (75.0) 10 (62.5) 4 (25.0) 
     








Quantitative 9 (36.0) 3 (33.3) 6 (66.6)  
Total 25    
5.1 Table 2: Distribution of Reviewed Articles by both Qualitative and Quantitative Methods of 
Recruitment of Women participants in HIV/AIDS Clinical Trials 
 
The research findings identified common barriers in recruitment and retention in HIV 
clinical trials for women. The four most common barriers reported among the female HIV/AIDS 





transportation.31 Other common barriers included language barriers, sensitivity to the study 
topic, safety of the treatment, inadequate research knowledge, and fear of research.32 
           Social stigma was reported as the most common barrier and was seen in 34.6% (n=9) of 
all reviewed articles in this study; lack of trust was reported as the second most common 
barrier and appeared in 24.0% (n=6); childcare and transportation together were reported as 











Female less likely to 
engage independently 
in research, negative 
experience 













5 (20.0)  
Limited access 
Location of sites 
needed to be closer to 
participants, flexibility 





Sensitivity to topic 3 (12.0) Personal topics of 











3 (12.0) Limited evidence of 
successful trials 
Staff Training and 
patient follow-up 
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Fear of Research 2 (8.0) Discussing or revisiting 
sensitive topics 
Debriefing after 
completion of a 
questionnaire 
5.2 Table 3: Data Results of Common Barriers of Recruitment and Retention of Women 
Participants in HIV/AIDS Clinical Trials with Common Best Practices 
*Total number of reviewed article 25 
As a result of the observations and surveys, several common best practices were found 
to increase women’s participation and retention in clinical HIV/AIDS studies. Researchers found 
that having a support group and a research staff member of a similar cultural background to 
facilitate the study helped with recruitment and retention of female participants. Having a 
supportive relationship between the study subject and research staff was also essential to 
maintain high retention rates in clinical trials. 
Chapter 6 
Discussion of Data Results 
Healthcare providers and researchers were able to identify and implement several 
common best practices to address these barriers. Participants were less likely to engage 
independently in research studies due to negative experiences relating to social stigma. In 
addressing negative social stigma, researchers found the best practice was to build a 
relationship between personnel and participants. Researchers wanted to remain transparent by 
giving the participants the opportunity to ask questions or voice their concerns to clarify any 
misconceptions or misinformation surrounding the research study. Researchers were able to 
provide more convenient study sites and appointment times to accommodate the participants’ 
lack of transportation and difficulties finding childcare. Healthcare providers observed that 





personnel with similar language and cultural backgrounds to assist with the language barrier. 
Clinical research staff acknowledged sensitive topics relating to HIV/AIDS and gave participants 
the opportunity to ask questions. Research coordinators who specialized in HIV clinical studies 
were hired to help participants who had inadequate knowledge about the research topic, or 
who were concerned about the safety of the trials. The clinical staff gave participants 
debriefings after the completion of clinical visits to address the participants’ fears and concerns 
relating to the studies. 
 Several recommendations can be made to implement these best practices to address 
the common barriers that resulted in the low recruitment and retention rates of female 
participants in future HIV/AIDS clinical studies. These recommendations include providing 
participants with monetary incentives, handing out brochures or fliers with research study 
information, using social media to spread awareness of the studies, offering online scheduling 
for appointments and follow-ups, offering video chat appointments, having an after-hour 
consultation service for questions or concerns, teaming with a local community center for 
support, hiring multilingual research staff or translators, providing online forms for surveys and 
questionnaires, and having in-house visits for participants unable to find childcare or 
transportation. 
6.1 Limitations 
There were several limitations in this study that may have impacted data analysis. While 
the initial literature search yielded a large number of existing articles, only 25 full-text articles 
relating to women’s participation in HIV/AIDS clinical trials were available for analysis for this 





personnel and healthcare providers' perspectives. These perspectives could have been 
substituted for the participants' actual clinical experience. Each HIV/AIDS clinical trial had a set 
of specific eligibility criteria, requirements, and inherent biases. Furthermore, what was 




 Based on the data found in this study, there were several common barriers to the 
recruitment and retention of female subjects in HIV/AIDS clinical trials. These barriers needed 
to be addressed to maximize the number of participants enrolled and to minimize the number 
of participant withdrawals. By acknowledging the common barriers and implementing the best 
practices found in this study, healthcare providers and researchers will be able to overcome the 
challenges in recruiting and retaining female participants in HIV/AIDS clinical trials. These 
common best practices, such as building relationships between patients and providers, 
acknowledging sensitive topics, training staff to be more knowledgeable about HIV/AIDS, 
showing empathy toward participants, and providing scheduling and location flexibility for 
patients, are some of the ways to help researchers improve the recruitment and retention rates 
of study subjects.  
Improving the recruitment and retention of women in HIV/AIDS clinical trials is essential 
to increase the validity of clinical trials and the knowledge for all persons, both male and 
female, due to gender-based differences in their responses to medical treatment. HIV/AIDS 





HIV/AIDS on the total population of infected persons of both sexes. Additional research 
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